EGPA (Churg-Strauss Syndrome): Managing Eosinophilic Inflammation and Flares

Most people with EGPA can describe the diagnosis in retrospect like a mystery novel where the clues were there all along. Severe asthma that didn't respond to normal treatment — refractory, unpredictable, different from what other people seemed to describe. Then eosinophilia on a blood panel, high enough to raise eyebrows. Then peripheral neuropathy, or skin lesions, or unexplained cardiac findings, or GI cramping that didn't fit anything simple. Then, eventually, the vasculitis picture came into focus.

Eosinophilic granulomatosis with polyangiitis — still often called Churg-Strauss syndrome — is one of the ANCA-associated vasculitides, though only about 40% of patients are ANCA-positive. Getting here usually takes years and passes through phases that make the final diagnosis feel simultaneously strange and clarifying.

The Three-Phase Architecture

EGPA is classically described in three overlapping phases. The first is the allergic or prodromal phase: asthma, allergic rhinitis, sinusitis — often severe and treatment-resistant. This can last years before the second phase emerges. The eosinophilic phase involves marked peripheral blood eosinophilia and eosinophilic tissue infiltration — lungs, GI tract, heart, skin — producing symptoms that can be mistaken for many things. The third, vasculitic phase is where the diagnosis typically becomes clear: inflammation of small-to-medium blood vessel walls, driven by eosinophilic infiltration and, in ANCA-positive cases, neutrophil-mediated endothelial damage.

These phases don't progress cleanly or linearly for everyone. Some people experience significant overlap. Some have the vasculitic picture emerge quickly; others live primarily in the eosinophilic phase for extended periods. What matters clinically is that the disease operates as a multi-system condition from relatively early on — even when the respiratory symptoms are the most obvious feature.

What Eosinophils Are Actually Doing

Eosinophils are ordinarily part of the immune defense against parasites — specialized cells that release cytotoxic proteins to kill large pathogens your immune system can't simply engulf. In EGPA, that machinery misfires. Eosinophils proliferate in response to sustained IL-5 signaling (driven by Th2 immune polarization), and when they infiltrate tissues, they release major basic protein, eosinophil cationic protein, and reactive oxygen species into whatever tissue they've entered.

Cardiac muscle exposed to this degranulation develops fibrosis and impaired function — Loeffler endocarditis, which can occur even without overt symptoms and is one reason cardiac surveillance is standard. Peripheral nerve sheaths exposed to eosinophil toxins develop the pattern of mononeuritis multiplex — foot drop, wrist drop, sensory loss — that's characteristic of EGPA neuropathy. In the GI tract, eosinophilic infiltration of the bowel wall produces cramping, diarrhea, and malabsorption. In the skin, purpura and subcutaneous nodules reflect both vascular and tissue eosinophilic involvement. The multi-system fatigue in EGPA isn't a vague symptom — it's the aggregate physiological cost of simultaneous eosinophilic damage across multiple organ systems.

The Respiratory-Immune Connection

The refractory asthma that defines EGPA's prodromal phase isn't a coincidence that later resolves into a separate vasculitis condition. The same underlying Th2 immune polarization drives both. Th2 dominance means overproduction of IL-4, IL-5, and IL-13: IL-4 drives IgE production and airway hyper-responsiveness, IL-13 promotes airway remodeling, and IL-5 drives eosinophil production and survival. The airways are, in this sense, the first visible expression of a broader immune dysregulation — the systemic eosinophilic and vasculitic disease is the same process unfolding beyond the lungs.

This is why airway management isn't separate from systemic inflammation management in EGPA. Reducing the overall Th2 burden — through anti-inflammatory diet, microbiome support, and stress management — supports both the respiratory and systemic picture.

Omega-3s and Eosinophilic Inflammation

There's a specific mechanism worth understanding here. EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) compete with arachidonic acid in the eicosanoid synthesis pathway, reducing production of leukotriene C4 and D4 — among the most potent eosinophil activators in allergic inflammation. EPA and DHA also suppress eosinophil chemotaxis: the process by which eosinophils are recruited from blood to inflamed tissue. Some research suggests omega-3 fatty acids modulate IL-5 signaling, reducing the primary cytokine driving eosinophil proliferation and survival.

This isn't a treatment for EGPA. It's a complementary mechanism that works through partially overlapping pathways to reduce eosinophilic activation. The Omega-3 Anti-Inflammation Complex is formulated around concentrated EPA and DHA for systemic anti-inflammatory support — relevant for eosinophilic inflammation in ways that go beyond general wellness.

Gut Eosinophilia and Microbiome Support

GI involvement in EGPA is more common than it's often discussed. Eosinophilic infiltration of the bowel wall causes pain, diarrhea, and malabsorption that's frequently attributed to other causes. Beyond the direct tissue involvement, the gut microbiome plays a role in Th2 immune conditioning: reduced microbial diversity and altered short-chain fatty acid production are associated with Th2 polarization broadly, including in atopic and eosinophilic conditions.

Supporting gut barrier integrity and microbiome diversity — through fiber-rich foods, fermented foods, and reducing gut-disrupting inputs like excess alcohol and ultra-processed foods — is one lever for shifting the immune environment at the source rather than downstream.

Stress Is a Biological Eosinophil Activator

This needs to be said clearly: in EGPA, stress management is not a lifestyle suggestion. It's a mechanistically relevant intervention. Corticotropin-releasing hormone (CRH), released during psychological and physiological stress, directly activates mast cells and promotes eosinophil degranulation. The stress hormone cascade also upregulates GATA-3, the master transcription factor for Th2 polarization — meaning sustained stress literally promotes the immune phenotype that drives eosinophilia. Managing stress isn't separate from managing EGPA; it's part of it.

Practical approaches: breathwork and slow-paced breathing can acutely reduce sympathetic nervous system activation. Regular, moderate exercise (when not flaring) modulates HPA axis reactivity. Sleep prioritization — because sleep deprivation amplifies stress hormone output — is more important than most treatment protocols acknowledge. The multi-system nature of EGPA flares is part of what makes the Flare Relief Comfort Kit a relevant resource — it's designed specifically for the kind of whole-body support needed during and after systemic autoimmune flares.

Living Alongside Biologics

Mepolizumab (Nucala), an anti-IL-5 antibody, is now approved specifically for EGPA and has changed the treatment landscape meaningfully — significant reductions in flare frequency, eosinophil counts, and often steroid requirements. If you're on mepolizumab or being evaluated for it, that's the right clinical conversation with your rheumatologist or immunologist.

What biologics don't address: the underlying Th2 immune conditioning, the gut microbiome, the dietary anti-inflammatory foundation, or the stress-eosinophil pathway. These remain active levers regardless of biologic therapy, and they compound with medication rather than competing with it.

EGPA is a condition that rewards treating the whole immune system as the unit of management, not just the eosinophil count. The people who do best long-term tend to be those who pull every lever available — consistently.